aktis oncology inc - AKTS
AKTS
Close Chg Chg %
18.55 -0.28 -1.51%
Closed Market
18.27
-0.28 (1.51%)
Volume: 134.31K
Last Updated:
May 11, 2026, 4:00 PM EDT
Company Overview: aktis oncology inc - AKTS
AKTS Key Data
| Open $18.66 | Day Range 17.88 - 18.98 |
| 52 Week Range N/A - N/A | Market Cap $993.30M |
| Shares Outstanding 53.40M | Public Float 29.26M |
| Beta 0.91 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.51 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 218.36K |
AKTS Performance
| 1 Week | 0.00% | ||
| 1 Month | 10.19% | ||
| 3 Months | 4.73% | ||
| 1 Year | N/A | ||
| 5 Years | N/A |
AKTS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About aktis oncology inc - AKTS
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.
AKTS At a Glance
Aktis Oncology, Inc.
17 Drydock Avenue
Boston, Massachusetts 02210
| Phone | 1-617-461-4023 | Revenue | 6.50M | |
| Industry | Pharmaceuticals: Major | Net Income | -63,731,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 336.92% | |
| Fiscal Year-end | 12 / 2026 | Employees | 79 | |
| View SEC Filings |
AKTS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
AKTS Efficiency
| Revenue/Employee | 82,240.506 |
| Income Per Employee | -806,721.519 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.022 |
AKTS Liquidity
| Current Ratio | 7.373 |
| Quick Ratio | 7.373 |
| Cash Ratio | 7.26 |
AKTS Profitability
| Gross Margin | 64.153 |
| Operating Margin | -1,149.515 |
| Pretax Margin | -980.93 |
| Net Margin | -980.93 |
| Return on Assets | -21.20 |
| Return on Equity | -29.446 |
| Return on Total Capital | -32.057 |
| Return on Invested Capital | -28.087 |
AKTS Capital Structure
| Total Debt to Total Equity | 6.167 |
| Total Debt to Total Capital | 5.809 |
| Total Debt to Total Assets | 4.277 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 5.147 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Aktis Oncology Inc - AKTS
Collapse All in section
| All values USD millions. | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 1.49M | 6.50M | - |
Sales Growth
| - | - | - | +336.92% | - |
Cost of Goods Sold (COGS) incl D&A
| - | 1.12M | 1.57M | 2.33M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | 1.12M | 1.57M | 2.33M | |
Depreciation
| - | 1.12M | 1.57M | 2.33M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | +40.62% | +47.87% | - |
Gross Income
| - | (1.12M) | (88.00K) | 4.17M | |
Gross Income Growth
| - | - | +92.14% | +4,836.36% | - |
Gross Profit Margin
| - | - | -5.92% | +64.15% | - |
| 2023 | 2024 | 2025 | 5-year trend | ||
|---|---|---|---|---|---|
SG&A Expense
| - | 33.67M | 51.96M | 78.85M | |
Research & Development
| - | 24.80M | 39.38M | 65.12M | |
Other SG&A
| - | 8.88M | 12.58M | 13.73M | |
SGA Growth
| - | - | +54.31% | +51.75% | - |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | (800.00K) | 8.00K | - |
EBIT after Unusual Expense
| - | (33.99M) | (52.06M) | (74.68M) | |
Non Operating Income/Expense
| - | 5.35M | 8.08M | 10.95M | |
Non-Operating Interest Income
| - | 5.38M | 8.10M | 11.01M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| - | (28.64M) | (43.98M) | (63.73M) | |
Pretax Income Growth
| - | - | -53.56% | -44.91% | - |
Pretax Margin
| - | - | -2,957.63% | -980.93% | - |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| - | (28.64M) | (43.98M) | (63.73M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| - | (28.64M) | (43.98M) | (63.73M) | |
Net Income Growth
| - | - | -53.56% | -44.91% | - |
Net Margin Growth
| - | - | -2,957.63% | -980.93% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| - | (28.64M) | (43.98M) | (63.73M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| - | (28.64M) | (43.98M) | (63.73M) | |
EPS (Basic)
| - | -0.614 | -0.8374 | -1.1934 | |
EPS (Basic) Growth
| - | - | -36.38% | -42.51% | - |
Basic Shares Outstanding
| - | 46.65M | 52.52M | 53.40M | |
EPS (Diluted)
| - | -0.614 | -0.8374 | -1.1934 | |
EPS (Diluted) Growth
| - | - | -36.38% | -42.51% | - |
Diluted Shares Outstanding
| - | 46.65M | 52.52M | 53.40M | |
EBITDA
| - | (33.67M) | (50.48M) | (72.36M) | |
EBITDA Growth
| - | - | -49.89% | -43.35% | - |
EBITDA Margin
| - | - | -3,394.42% | -1,113.67% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 31.75 | |
| Number of Ratings | 6 | Current Quarters Estimate | -0.373 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -1.44 | |
| Last Quarter’s Earnings | -0.35 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.83 | Next Fiscal Year Estimate | -1.881 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 5 | 6 | 6 |
| Mean Estimate | -0.37 | -0.41 | -1.44 | -1.88 |
| High Estimates | -0.29 | -0.31 | -0.77 | -1.05 |
| Low Estimate | -0.42 | -0.46 | -1.72 | -2.65 |
| Coefficient of Variance | -13.17 | -14.62 | -26.42 | -33.02 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Aktis Oncology Inc - AKTS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Aktis Oncology Inc - AKTS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Apr 17, 2026 | Glenn Gormley Director | 37,866 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | N/A | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | VV Manager LLC | N/A | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | VV Manager LLC | N/A | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | VV Manager LLC | N/A | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | VV Manager LLC | N/A | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | VV Manager LLC | 157,387 | Open market or private purchase of non-derivative security Non-derivative transaction at $18 per share | 2,832,966.00 |
| Feb 25, 2026 | VV Manager LLC | 134,842 | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | VV Manager LLC | 5,671,825 | Open market or private purchase of non-derivative security Non-derivative transaction at $18 per share | 102,092,850.00 |
| Feb 25, 2026 | VV Manager LLC | 4,859,370 | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | 2,270,879 | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | N/A | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | N/A | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | N/A | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | N/A | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | 347,305 | Open market or private purchase of non-derivative security Non-derivative transaction at $18 per share | 6,251,490.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | 4,348,658 | Open market or private purchase of non-derivative security Non-derivative transaction at $18 per share | 78,275,844.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | 128,506 | Conversion of derivative security | 0.00 |
| Feb 25, 2026 | EcoR1 Capital, LLC Director | 202,862 | Conversion of derivative security | 0.00 |